Current Treatment Landscape in Relapsed/Refractory Marginal Zone Lymphoma

Treatment for relapsed or refractory marginal zone lymphoma is guided by disease biology and prior therapy. Traditional approaches such as chemoimmunotherapy remain options, but recent developments in targeted and immune-based treatments are reshaping care. These therapies aim to deliver effective disease control with fewer systemic adverse effects, improving both outcomes and daily well-being.

The first-line approach typically focuses on balancing efficacy and quality of life, while second-line strategies emphasize personalization. Treatment selection considers disease location, symptom burden, and individual tolerance. For patients whose disease returns, newer immunotherapy and precision agents are helping achieve deeper and more sustained remissions.

The expanding therapeutic landscape allows for more flexibility and hope. Clinicians now have multiple tools to sequence care based on response, adverse effect management, and patient preference, ensuring a holistic, patient-centered approach.